Clinical profiles in acute heart failure: an urgent need for a new approach. (25th April 2019)

• Record Type: Journal Article
• Authors: Chapman, Brittany; DeVore, Adam D.; Mentz, Robert J.; Metra, Marco
• Is Part Of: ESC heart failure. Volume 6:Number 3(2019)
• Page Start: 464
• Page End: 474
• Publication Date: 2019-04-25
• Subjects: Acute heart failure -- Classification -- Clinical trials; Heart failure -- Periodicals; 616.129005
• DOI: 10.1002/ehf2.12439
• Languages: English
• ISSNs: 2055-5822

Abstract

Abstract: Acute heart failure (HF) is a major public health concern, responsible for >26 million hospitalizations per year worldwide. Many trials have investigated new therapeutic options for acute HF, with most revealing equivocal results. Successful innovations in therapy for acute HF have remained limited, and standard of care has remained largely unchanged over the past decade, suggesting the need for a new approach for therapeutic decision making and clinical trial design in acute HF. This manuscript focuses on one approach that could prove useful in the development and application of novel therapies: classification of patients based on clinical profiles. While previous attempts at developing clinical profiles were successful in stratifying patients based on clinical and laboratory variables, they have not been utilized for personalized treatment strategies that improve patient outcomes. We suggest a new approach to the creation of clinical profiles that could stratify patients based on their underlying aetiology and their response to novel interventions. We also investigate novel analytic approaches to the creation of new clinical profiles that both investigators and clinicians alike could utilize to inform clinical trial design and the application of new therapies. Despite a large number of clinical trials for new therapeutic options, the treatment of acute HF has seen few advances over the past decades. Innovative approaches to patient selection through the use of clinical profiles could help to identify patients most likely to benefit from novel interventions and lead to the discovery of new therapeutic options.